Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini represented Aadi Bioscience, Inc. on the deal. Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal while Goodwin Procter represented Redmile Group. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living...
You must be a Standard 1 Year member to access this content.
